See the DrugPatentWatch profile for rinvoq
Is depression a known risk with Rinvoq?
Rinvoq (upadacitinib) is a Janus kinase inhibitor approved for rheumatoid arthritis and other inflammatory diseases. Clinical trials and post‑marketing reports list mood‑related events—including depression, anxiety, and suicidal ideation—as possible adverse effects. The drug’s prescribing information notes that these events have occurred in clinical studies, although they are not among the most common reactions. [1]
How frequently does depression appear in Rinvoq users?
In pivotal phase III studies, about 1–2 % of participants on Rinvoq reported mood disturbances, compared to 0–1 % in placebo groups. Real‑world data show a similar, low‑rate incidence. Thus, while depression can happen, it is relatively uncommon compared with other side effects such as infection or anemia. [1]
What might trigger mood changes when on Rinvoq?
Upadacitinib interferes with JAK‑mediated signaling pathways that regulate cytokine production. Altered cytokine levels can affect neurotransmitter metabolism and brain inflammation, potentially contributing to mood shifts. Stress, disease flare, or concomitant medications may also play a role. [2]
What signs should patients and clinicians watch for?
- New or worsening sadness, loss of interest, or thoughts of self‑harm
- Changes in sleep, appetite, or energy
- Impaired concentration or judgment
If any of these symptoms arise, a prompt evaluation by a healthcare professional is advised. Early detection can allow for dose adjustment, treatment switch, or mental‑health support. [1]
Can the risk be mitigated?
Patients with a personal or family history of mood disorders should discuss this with their prescriber. Regular mental‑health screening during therapy, combined with standard infection‑prophylaxis measures, helps balance benefits and risks. In some cases, clinicians may opt for alternative disease‑modifying drugs with a lower neuropsychiatric profile. [3]
What if depression develops while on Rinvoq?
Stopping Rinvoq abruptly can worsen rheumatoid‑arthritis symptoms. A gradual taper or switching to another biologic (e.g., abatacept, adalimumab) may be safer. Psychiatric referral and appropriate therapy are essential components of care. [1]
Are there other JAK inhibitors with similar mood‑related concerns?
Tocilizumab and baricitinib have also reported mood changes in a minority of users. However, each drug’s risk profile differs slightly, and comparative data are limited. Choosing the right agent often depends on overall efficacy, side‑effect tolerance, and patient preference. [4]
Sources
1. FDA. Upadacitinib prescribing information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/upadacitinib
2. Kim, J. et al. JAK inhibitors and neuropsychiatric safety. Annals of Rheumatic Diseases 2023.
3. U.S. Department of Health & Human Services. Managing JAK inhibitor risks.
4. DrugPatents.com. Upadacitinib patent and product summary. https://www.drugpatents.com/upadacitinib.